Eupraxia Pharmaceuticals Inc(EPRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.98 | Insider Own | 18.62% | Shs Outstand | 65.5M | Perf Week | -4.48% |
| Market Cap | 0.47B | Forward P/E | - | EPS next Y | -12.58% | Insider Trans | - | Shs Float | 52.9M | Perf Month | -20.33% |
| Enterprise Value | 0.37B | PEG | - | EPS next Q | -0.27 | Inst Own | 40.86% | Short Float | 12.36% | Perf Quarter | 13.28% |
| Income | -0.05B | P/S | - | EPS this Y | 14.7% | Inst Trans | 2.48% | Short Ratio | 10.4 | Perf Half Y | -7.05% |
| Sales | 0.00B | P/B | 4.67 | EPS next 5Y | -3.97% | ROA | -61.39% | Short Interest | 6.54M | Perf YTD | -3.97% |
| Book/sh | 1.55 | P/C | 3.53 | EPS past 3/5Y | -2.38% -34.75% | ROE | -65.25% | 52W High | -22.21% ($9.32) | Perf Year | 33.27% |
| Cash/sh | 2.06 | P/FCF | - | Sales past 3/5Y | - | ROIC | -37.75% | 52W Low | 38.1% ($5.25) | Perf 3Y | 83.17% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -16.42% | Gross Margin | - | Volatility(W/M) | 7.86% 7.7% | Perf 5Y | 222.22% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.5 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16 | EPS Q/Q | 12.82% | Profit Margin | - | RSI (14) | 48.29 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16 | Sales Q/Q | - | SMA20 | 0.13% ($7.24) | Beta | 1.14 | Target Price | $15.86 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | -4.5% ($7.59) | Rel Volume | 1.62 | Prev Close | $7.38 |
| Employees | 49 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 1.34% - | SMA200 | -0.9% ($7.32) | Avg Volume(3M) | 0.63M | Price | $7.25 |
| IPO | 2021/8/3 | Option/Short | No/Yes | Trades | 3672 | Volume | 1,015,484 | Change | -1.76% |
A clinical-stage biotech company developing therapeutics for inflammatory and pain-related diseases based on its proprietary long-acting drug delivery platform, DiffuSphere. Operating primarily in the U.S. and Canada, the company is advancing injectable candidates targeting conditions such as eosinophilic esophagitis (EoE) and knee osteoarthritis pain.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
Traded more than usual. That is 162% of its average volume.
EPRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +14.7% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to miss estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +222.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 40.9%.
Tap to view numbers
It ranks #227 of 594 in the industry
Based on market cap of $471M.
FTH#224 Faeth Therapeutics Inc $485M PER - 
BLSM#225 BlossomHill Therapeutics Inc $483M PER - 
MNPR#226 Monopar Therapeutics Inc $483M PER - EPRX#227 Eupraxia Pharmaceuticals Inc $471M PER - 
PRTA#228 Prothena Corp Plc $456M PER - 
FAQ
What kind of company is EPRX?
EPRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EPRX?
The market cap of EPRX is approximately $471M, ranking 3,209 within its sector.
What is the 52-week high and low for EPRX?
EPRX has recorded a 52-week high of $9.32 and a low of $5.25.
